다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Psychiatry investigation, v.7 no.3, 2010년, pp.228 - 230
Park, Young-Min (Department of Neuropsychiatry, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.) , Lee, Bun-Hee (KARF Hospital, Goyang, Korea.) , Lee, Heon-Jeong (Department of Psychiatry, Anam Hosipital, Korea University College of Medicine, Seoul, Korea.) , Kang, Seung-Gul (Saessac Hospital, Uijeongbu, Korea.)
AI-Helper
Duloxetine is a balanced and potent serotonin and noradrenaline reuptake inhibitor (SNRI) and has adverse effects that are commonly associated with such drugs, including nausea, dry mouth, constipation, insomnia, and dizziness. Recently, duloxetine-induced liver injury has also been observed in pati...
1 Hudson JI Wohlreich MM Kajdasz DK Mallinckrodt CH Watkin JG Martynov OV Safety and tolerability of duloxetine in the treatment of major depressivedisorder: analysis of pooled data from eight placebo-controlled clinical trials Hum Psychopharmacol 2005 20 327 341 15912562
2 CYMBALTA (duloxetine hydrochloride) delayed-release capsules Product labeling 2005 Indianapolis, IN Eli Lilly and Company
3 Wernicke J Acharya N Strombom I Gahimer JL D'Souza DN DiPietro N Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events Curr Drug Saf 2008 3 143 153 18690992
4 Björnsson E Drug-induced liver injury: Hy's rule revisited Clin Pharmacol Ther 2006 79 521 528 16765139
5 Ostapowicz G Fontana RJ Schiødt FV Larson A Davern TJ Han SH Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States Ann Intern Med 2002 137 947 954 12484709
6 Bleibel W Kim S D'Silva K Lemmer ER Drug-induced liver injury: review article Dig Dis Sci 2007 52 2463 2471 17805971
7 Holt MP Ju C Mechanisms of drug-induced liver injury AAPS J 2006 8 E48 E54 16584133
8 McIntyre RS Panjwani ZD Nguyen HT Woldeyohannes HO Alsuwaidan M Soczynska JK The hepatic safety profile of duloxetine: a review Expert Opin Drug Metab Toxicol 2008 4 281 285 18363543
9 Wohlreich MM Acharya N Strombom I Kuritzky L Robinson M Heinloth AN Answers to the most common questions about the hepatic safety profile of duloxetine Postgrad Med 2008 120 111 118 18654076
10 Raskin J Wang F Pritchett YL Goldstein DJ Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study Pain Med 2006 7 373 385 17014595
11 Wernicke J Pangallo B Wang F Murray I Henck JW Knadler MP Hepatic effects of duloxetine-I: non-clinical and clinical trial data Curr Drug Saf 2008 3 132 142 18690991
12 Hanje AJ Pell LJ Votolato NA Frankel WL Kirkpatrick RB Case report: fulminant hepatic failure involving duloxetine hydrochloride Clin Gastroenterol Hepatol 2006 4 912 917 16797245
13 Lucena MI Carvajal A Andrade RJ Velasco A Antidepressant-induced hepatotoxicity Expert Opin Drug Saf 2003 2 249 262 12904104
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.